Edition:
United States

Microbix Biosystems Inc (MBX.TO)

MBX.TO on Toronto Stock Exchange

0.26CAD
10:35am EDT
Change (% chg)

$0.01 (+4.00%)
Prev Close
$0.25
Open
$0.26
Day's High
$0.26
Day's Low
$0.26
Volume
4,308
Avg. Vol
53,004
52-wk High
$0.34
52-wk Low
$0.18

Latest Key Developments (Source: Significant Developments)

Microbix Qtrly earnings per share $0.010
Friday, 23 Dec 2016 08:00am EST 

Microbix Biosystems Inc : Qtrly earnings per share $ 0.010 . Microbix reports fiscal 2016 results continued profitability and strong revenue growth .Q4 revenue C$3.471 million versus C$2.114 million.  Full Article

Microbix Q4 earnings per share $0.010
Friday, 23 Dec 2016 08:00am EST 

Microbix Biosystems Inc : Qtrly earnings per share $0.010 . Microbix Biosystems Inc - continuing development of its new molecular controls product line, expects to launch new product offering later in 2017 . Microbix reports fiscal 2016 results continued profitability and strong revenue growth .Q4 revenue C$3.471 million versus C$2.114 million.  Full Article

Microbix Biosystems's CFO Charles Wallace to retire
Tuesday, 1 Nov 2016 08:30am EDT 

Microbix Biosystems Inc : Microbix appoints new chief financial officer . Microbix Biosystems Inc says Jim Currie is joining company on November 1, 2016 as newly appointed chief financial officer .Microbix Biosystems Inc says Charles Wallace, company's chief financial officer, is retiring on December 31, 2016.  Full Article

Microbix Biosystems Q3 net income per share $0.001
Monday, 15 Aug 2016 07:45am EDT 

Microbix Biosystems Inc : Q3 revenue rose 2 percent to C$2.253 million . Microbix revenue continues to grow in third quarter . "discussions continue" with global animal genetics companies to secure partnership to complete Lumisort Development Program . Qtrly net income per share $0.001 .Expect "continued strong sales performance" in q4 based on significant shipments in July, customer orders for delivery in this quarter.  Full Article

Microbix Biosystems reports Q2 earnings per share $0.002
Monday, 16 May 2016 07:21am EDT 

Microbix Biosystems Inc : Qtrly earnings per share $0.002 . Qtrly net income per share $0.002 . Q2 revenue rose 7 percent to c$2.73 million . Confirmed that discussions continue with global animal genetics companies for partnership to complete lumisort development program .Discussions progressing with third parties for funding commitment to re-launch kinlytic in u.s., canada and international markets.  Full Article

Microbix Biosystems Inc announces delay in filing of annual financial statements
Wednesday, 30 Dec 2015 05:00pm EST 

Microbix Biosystems Inc:Announces that it has not filed its required filings by the prescribed deadline of December 29, 2015.Company was unable to file the Required Filings as a result of a delay in the completion of its audit.  Full Article

Microbix Biosystems Inc closes private placement
Tuesday, 13 Oct 2015 08:30am EDT 

Microbix Biosystems Inc:Confirms closing of a private placement financing resulting in the issuance of 940,000 units at a price of $0.40 per unit for gross proceeds of $376,000.Financing was non-brokered.  Full Article

Microbix Biosystems launches two new antigens to diagnose Toxoplasma Gondii
Tuesday, 9 Jun 2015 08:33am EDT 

Microbix Biosystems Inc:Says the commercial introduction of two new Toxoplasma Gondii products targeted at immunoassay manufacturers looking for improved sensitivity and specificity of diagnostic tests.  Full Article

Microbix Biosystems Inc Provides Update on U.S. VIRUSMAX Litigation
Friday, 15 May 2015 08:27am EDT 

Microbix Biosystems Inc:Says U.S. District Court in the Eastern District of Texas has provided its decisions on a litigation between Microbix and Novartis.Says In the matter of whether Novartis has infringed the 18 patent claims asserted by Microbix on its patent 7,270,990 in the United States, the court ruled in favour of Novartis, the defendant.Says Concerning the defendant's counterclaim seeking a declaratory judgment of patent invalidity, the court dismissed it without prejudice.Says Court administration costs, which are not expected to be material, are the responsibility of Microbix.Says it is reviewing the ruling of the Court and assessing its approaches to enforcing the patent claims relating to its VIRUSMAXÂ technology.  Full Article

More From Around the Web

BRIEF-Microbix Biosystems's CFO Charles Wallace to retire

* Microbix Biosystems Inc says Jim Currie is joining company on November 1, 2016 as newly appointed chief financial officer

No consensus analysis data available.